TIPCO GROUP combines technology, expertise, and scientific insight to transform healthcare delivery. Our holistic approach is designed to improve clinical outcomes and optimize the experience for healthcare providers and patients alike.
CMS pushes back new skin-substitute coverage rules to Jan 1, 2026
The Centers for Medicare & Medicaid Services (CMS) has delayed the effective date of its Local Coverage Determinations (LCDs) for skin substitute grafts—impacting placental allografts—until January 1, 2026, citing a broader review to maintain patient access
Read Full ArticleFilter News
CMS pushes back new skin-substitute coverage rules to Jan 1, 2026
The Centers for Medicare & Medicaid Services (CMS) has delayed the effective date of its Local Coverage Determinations (LCDs) for skin substitute grafts—impacting placental allografts—until January 1, 2026, citing a broader review to maintain patient access
BioStem completes enrollment in DFU trial of amnion-chorion allograft (BioRETAIN)
BioStem Technologies has finished enrolling 71 patients in a clinical trial evaluating its amnion-chorion placental allograft (BioRETAIN) for diabetic foot ulcers (DFUs); topline data are expected in Q4 2025.
2026 Physician Fee Schedule proposal would standardize payment for all “skin substitutes”
In the CY 2026 Physician Fee Schedule Proposed Rule, CMS outlines a single national payment rate (~$125.38/cm²) and shifts certain skin-substitute payments to incident-to supplies, changes that could reshape pricing dynamics for placental allografts in physician offices.
Let's Build Healthier Solutions Together
Get in touch with our team to discuss your healthcare needs